Cutaneous Lymphoma
9
1
2
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 74/100
22.2%
2 terminated out of 9 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
T-VEC in Non-melanoma Skin Cancer
Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous Lymphomas
Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma
Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level
Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing
ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor Cells